- Home
- RPRX vs UTHR Comparison
RPRX vs UTHR Comparison
Compare RPRX & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- UTHR
- Stock Information
- Founded
- RPRX 1996
- UTHR 1996
- Country
- RPRX United States
- UTHR United States
- Employees
- RPRX N/A
- UTHR N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- RPRX Health Care
- UTHR Health Care
- Exchange
- RPRX Nasdaq
- UTHR Nasdaq
- Market Cap
- RPRX 15.6B
- UTHR 13.8B
- IPO Year
- RPRX 2020
- UTHR 1999
- Fundamental
- Price
- RPRX $35.15
- UTHR $403.11
- Analyst Decision
- RPRX Strong Buy
- UTHR Strong Buy
- Analyst Count
- RPRX 3
- UTHR 15
- Target Price
- RPRX $45.33
- UTHR $449.13
- AVG Volume (30 Days)
- RPRX 3.9M
- UTHR 894.2K
- Earning Date
- RPRX 11-05-2025
- UTHR 10-29-2025
- Dividend Yield
- RPRX 2.50%
- UTHR N/A
- EPS Growth
- RPRX 54.86
- UTHR 17.94
- EPS
- RPRX 2.32
- UTHR 25.63
- Revenue
- RPRX $2,305,243,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- RPRX $33.77
- UTHR $13.89
- Revenue Next Year
- RPRX $4.62
- UTHR $5.68
- P/E Ratio
- RPRX $15.12
- UTHR $15.73
- Revenue Growth
- RPRX 3.02
- UTHR 17.62
- 52 Week Low
- RPRX $24.05
- UTHR $266.98
- 52 Week High
- RPRX $38.00
- UTHR $436.95
- Technical
- Relative Strength Index (RSI)
- RPRX 40.78
- UTHR 70.30
- Support Level
- RPRX $35.97
- UTHR $395.00
- Resistance Level
- RPRX $36.94
- UTHR $407.06
- Average True Range (ATR)
- RPRX 0.85
- UTHR 13.35
- MACD
- RPRX -0.06
- UTHR 4.82
- Stochastic Oscillator
- RPRX 33.46
- UTHR 74.89
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.